David Paje

physician, educator, student, researcher, veteran, and nature lover

[David Paje @PajeDavid]

#vascularaccess is critical for the survival of patients with advanced #chronickidneydisease. Physicians should be mindful when ordering #PICCs for these patients. From @umichmedicine @UMich @HMS_MI @AnnalsofIM https://t.co/spXrA5CMnL

[Ajay Major, MD, MBA @majorajay]

Elated to be presenting our MAGIC-ONC vascular access appropriateness recommendations in patients with cancer to the @HMS_MI consortium today!
Be sure to read the full paper published @AnnalsofIM: https://t.co/EGvNqSJJ45 #onctwitter

[Ajay Major, MD, MBA @majorajay]

Announcing the MAGIC-ONC guidelines for the placement and management of vascular access devices in patients with cancer, including specific recommendations for both hematologic and solid tumor malignancies. #MAGICOnc #onctwitter
https://t.co/OTgiODb8Te

[Ajay Major, MD, MBA @majorajay]

Late night publication (finally!) of our MAGIC-ONC appropriateness guidelines for vascular access in patients with cancer. More to come tomorrow! #medtwitter #onctwitter https://t.co/aCsY8pnXoe

[Vineet Chopra @vineet_chopra]

Today, I am pleased to share the release of #MAGICOnc to the world.

https://t.co/MPcrcbXdRH

#MAGICOnc builds on the legacy of #MAGIC (https://t.co/U6FYH5kpAL) in providing evidence-based guidance on what vascular device is most appropriate for patients with cancer.

[Vineet Chopra @vineet_chopra]

There's more in the full paper! Please take a look, share and most importantly IMPLEMENT and TEST in your patients with cancer.

Im grateful to @HMS_MI @PajeDavid @majorajay for leading this work. I truly hope it will bring better outcomes to patients!

[Ajay Major, MD, MBA @majorajay]

Deeply thankful to Dr. @vineet_chopra as well as Dr. @PajeDavid for their mentorship in bringing MAGIC-ONC to fruition!
We look forward to your feedback on these appropriateness guidelines, and encourage you to implement and test them in your patients with cancer. #onctwitter

[Michigan HMS @HMS_MI]

🚨 Just published: MAGIC-ONC — a new international framework to guide vascular access decisions in #cancer care. By treating VAD selection as a modifiable risk, we can improve outcomes & reduce harm.

https://t.co/IjwktGGPAA #MAGICONC #Oncology #VascularAccess #PatientSafety

[Michigan HMS @HMS_MI]

🚨 Are midline catheters a safe choice for vancomycin OPAT?

Despite guideline caution, evidence is limited. Using @HMS_MI data, we explored complication risks in hospitalized patients receiving OPAT—with & without vancomycin.

Clinical dogma, meet data. 💉📊 #PatientSafety #OPAT

[David Paje @PajeDavid]

Findings from @HMS_MI:

Administration of extended courses of vancomycin via midline catheters is associated with higher risks of serious complications and device failure.

This highlights importance of medication & vascular access device compatibility.

https://t.co/9ImXf97WAH

[Michigan HMS @HMS_MI]

🌼 HMS is celebrating Nurses Week by honoring those who champion quality and safety behind the scenes. Your dedication ensures that every patient receives the highest quality of care possible. 🩺

Thank you for your unwavering commitment to excellence! 🙏

#NursesWeek25

[David Paje @PajeDavid]

Always a pleasure to share what we learn from @HMS_MI!
Grateful for the opportunity to meet with and be inspired by the high-performing and impressive team at @CUDivHospMed!
#highqualityvascularaccess

[CU Anschutz Hospital Medicine @CUDivHospMed]

We recently hosted Dr. David Paje from the University of Michigan for our Visiting Professor program! He presented “Midline Catheters in Contemporary Clinical Practice,” sparking insightful discussion & collaboration. Thank you for joining us and advancing our clinical knowledge!

[Journal of Hospital Medicine @JHospMedicine]

📊💡 New evidence shows how hospitalist Medical Procedure Services (MPS) improve outcomes! MPS cuts length of stay, enables weekend procedures, & boosts same-day discharges. #PatientCare

🔗: https://t.co/dyqEFTayzH
✍️:@PajeDavid, @StephptaylorCLT, @curtisy_call

[JAMA Internal Medicine @JAMAInternalMed]

Midline catheters used for outpatient parenteral antimicrobial therapy (OPAT) had a lower risk of major complications compared to PICCs, especially for treatments lasting 14 days or fewer.

https://t.co/3CU64Vhdpg

[Michigan HMS @HMS_MI]

‼️ New findings from #HMS suggest that midline catheters are safe alternatives to PICCs for OPAT, especially for treatment durations of 14 or fewer days.

Read the @JAMAInternalMed publication here 👉https://t.co/fbTSafwKMj

[Vineet Chopra @vineet_chopra]

New paper hot off the press from @JAMAInternalMed. Congrats to @PajeDavid for leading this effort!

What's better for #OPAT? Midlines or PICCs? And what duration is best for both devices?

https://t.co/u7PQAfKUll

[Michigan HMS @HMS_MI]

On 11/21/24, @MiAVANetwork is hosting its fall conference and vendor fair in Ann Arbor. Use the QR code to register and listen to five excellent speakers discuss vascular access. #HMS #PICC Physician lead Dr. @PajeDavid will share our journey in improving PICC/midline practice.

[Vineet Chopra @vineet_chopra]

Big day today - a group of international thought leaders - hematologists, oncologists, IR, ID, etc. all coming together to create #MAGICOnc - appropriateness reccs for vascular access in #Cancer.

Stay tuned for final reccs coming to a journal near you!

[Stephanie Parks Taylor @StephptaylorCLT]

Improving mobility for hospitalized patients is a high-priority research area for U-M hospital medicine!

Congrats to HM research project manager and @umichDLHS MEL-STAR scholar @TrevDenton on presenting his important LHS work on digital innovation for getting patients to move!

[Michigan HMS @HMS_MI]

Great presentation this morning at AVA 2024 on the importance of vein preservation in patients with renal failure/impairment. Always nice to see our HMS data shared at National Conferences!

[Michigan HMS @HMS_MI]

HMS Rockstars @vineet_chopra @PajeDavid @engineertodoc presenting at AVA 2024 on our Midline Initiative! It is such a privilege to help inform best practices and national standards for vascular device use.